The contribution provides a comprehensive overview of the legislative and regulatory landscape in Serbia for the life sciences industry. We examined the organisation and financing of healthcare structures, the regulatory environment for provision of healthcare services, rules on data protection, privacy and digitisation of healthcare, advertising, collaboration of the pharmaceutical industry with healthcare professionals, infringements of competition law, compliance on the part of medicines and medical device manufacturers, as well as pricing and reimbursement of medicinal products. We take notice of the temporary emergency measures concerning the healthcare industry which the state authorities adopted in response to the coronavirus outbreak.
The Serbia chapter in Life Sciences 2021 can be downloaded here. Reproduced with permission from Law Business Research Ltd. This content was first published in Lexology GTDT: Life Sciences 2021, November 2020. For further information please visit https://www.lexology.com/gtdt/workareas/life-sciences.